Avanos Medical, Inc. Announces Third Quarter 2021 Results

Rhea-AI Summary

Avanos Medical reported Q3 2021 financial results with net sales of $184 million, a decrease of less than 1% from the previous year. The company faced a net loss of $35 million, contrasting with a net income of $19 million from last year. Operating cash flow was $23 million, bolstered by $47 million in tax refunds. Despite challenges in acute pain due to elective procedure delays, operational metrics improved, including adjusted net income of $12 million. The gross margin stood at 49%, down from 52% last year, attributed to rising freight costs.

Positive

• Operating cash flow reached $23 million, aided by tax refunds.
• Adjusted net income increased to $12 million from $10 million a year ago.
• Operating profit improved to $4 million, up from a small operating loss last year.

Negative

• Net loss of $35 million compared to net income of $19 million a year ago.
• Gross margin decreased to 49% from 52% due to higher freight costs.
• Decline in net sales and volume in Respiratory Health due to pandemic effects.

ALPHARETTA, Ga., Nov. 2, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2021 financial results.

"We continue to see unevenness in the recovery across our product portfolio but are very pleased with our overall execution. While there were headwinds in acute pain resulting from continued delays and postponements of elective surgical procedures, we met or exceeded all of our other priorities and made meaningful progress in improving our gross profit margins through the third quarter" stated Joe Woody, Avanos' chief executive officer.

Woody continued, "we anticipate gross margin further improving into the end of the year and throughout 2022, which combined with our continued spending discipline, will enhance our profitability measures meaningfully."

Operational and Business Highlights

• Operating cash flow of $23 million in the quarter was driven by $47 million of income tax refunds received associated with the CARES Act.
• The annual Spine Intervention Society selected our study for podium presentation that used magnetic resonance imaging to visualize cooled radiofrequency ablation lesions and was awarded the "Best Science" award for the conference, highlighting our commitment to science and research.
• In August, the American Academy of Orthopedic Surgeons included genicular radiofrequency ablation in their treatment guidelines for the first time. While COOLIEF* was not specifically mentioned, the Academy called out a clinical study we previously published as a "high quality study."
• In September, the American Society for Pain and Neuroscience specifically mentioned that cooled probes, like those used in COOLIEF*, create larger lesions and increase the likelihood of treatment success.

Third Quarter 2021 Financial Highlights

• Net sales totaled $184 million, a less than 1 percent decrease from the prior year.
• Net loss for the quarter was $35 million, compared to net income of $19 million a year ago.
• Adjusted net income totaled $12 million, compared to $10 million a year ago.
• Diluted loss per share was $0.73, compared to earnings of $0.40 a year ago.
• Adjusted diluted earnings per share were $0.25, compared to $0.21 in the prior year.

Third Quarter 2021 Operating Results

Net sales totaled $184 million, a decrease of less than 1 percent compared to the prior year due to slightly unfavorable pricing. Volume was flat in the pain business with improvements in Interventional Pain due to favorable comparisons to last year's sales. In addition, volume benefited from continued strong demand for Digestive Health offset by lower volume in Respiratory Health due to the pandemic-fueled demand experienced last year.

Gross margin was 49 percent, compared to 52 percent a year ago. Adjusted gross margin was 52 percent, down due primarily to higher freight costs and inefficiencies at our manufacturing plants, compared to 55 percent last year.

Operating profit was $4 million compared to a small operating loss a year ago due to lower general and administrative expenses with savings realized from the restructuring activities undertaken at the end of 2020, as well as the continued discipline of spend throughout 2021. On an adjusted basis, operating profit totaled $17 million, compared to $18 million a year ago.

Adjusted EBITDA for the quarter was $22 million, compared to $24 million in the prior year.

First Nine Months 2021 Operating Results

Net sales were $551 million, an increase of 4 percent compared to the prior year. Volume increased 4 percent driven by our pain management franchise due to the recovery of elective surgical procedures and favorable comparison to last year's sales which were negatively impacted by the COVID-19 pandemic. In addition, volume benefited from continued robust demand for Digestive Health, which was partially offset by lower volume in Respiratory Health due to the pandemic-fueled demand experienced last year. Volume growth was partially offset by slightly unfavorable price and mix, while foreign currency exchange rates provided a 1 percent benefit.

Gross margin was 49 percent, compared to 54 percent last year. Adjusted gross margin was 52 percent, down due primarily to higher freight costs and inefficiencies at our manufacturing plants, compared to 56 percent last year.

Operating loss was $16 million compared to operating loss of $1 million a year ago due to non-cash restructuring costs related to the previously announced restructuring in the fourth quarter of 2020 and legal expense in connection with the resolution of the DOJ's investigation related to the company's MicroCool surgical gowns. On an adjusted basis, operating profit was $48 million compared to $45 million a year ago driven by higher sales and significantly lower total operating expenses, offsetting lower than anticipated gross margin.

Adjusted EBITDA for the nine-month period was $64 million compared to $63 million in the prior year.

Cash Flow and Balance Sheet

Cash from operations less capital expenditures, or free cash flow, for the quarter was $18 million, compared to an outflow of $2 million a year ago. The Company's cash balance was $98 million at the end of the quarter, compared to $112 million at year-end 2020.

Total debt outstanding on our revolving credit facility was $145 million at the end of the third quarter compared to $180.0 million at the end of last year. In the nine months ended September 30, 2021, we borrowed $20.0 million and repaid $55 million on our revolving credit facility.

Non-GAAP Financial Measures

This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:

• Adjusted gross profit and margin
• Adjusted operating profit
• Adjusted income before tax
• Adjusted tax provision and effective tax rate
• Adjusted net income
• Adjusted diluted earnings per share
• Adjusted EBITDA
• Free cash flow

These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:

• Incremental expenses associated with altering operations in response to the COVID-19 pandemic.
• Expenses associated with restructuring activities, including IT-related charges.
• Expenses associated with post divestiture transition activities.
• Certain acquisition and integration charges related to acquisitions.
• Expenses associated with European Union Medical Device Regulation ("EU MDR") compliance.
• Expenses associated with certain litigation matters.
• The amortization of intangible assets associated with prior business acquisitions.
• The tax effects of the adjusting items.
• Benefit associated with tax effects of the CARES Act.
• The positive or negative effect of changes in currency exchange rates during the year.

The Company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the Company's Board of Directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating profit, adjusted EBITDA, and free cash flow to (a) evaluate the Company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the Company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations.

Additionally, the Compensation Committee of the Company's Board of Directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company's net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.

Conference Call Webcast

Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. The conference call can be accessed live over the Internet at https://avanos.investorroom.com or via telephone by dialing 877-240-5772 in the United States. A replay of the call will be available at noon ET today by calling 877-344-7529 in the United States and entering passcode 10160764. A webcast of the call will also be archived in the Investors section on the Avanos website.

About Avanos Medical, Inc.

Avanos Medical (NYSE: AVNS) is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Forward-Looking Statements

This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue" and similar expressions, among others. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; risks related to the ongoing COVID-19 pandemic; shortage in drugs used in our Acute Pain products or other disruptions in our supply chain; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.

AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)
(in millions, except per share amounts)
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
Net Sales			$	184.1					$	185.7					$	551.2					$	529.8
Cost of products sold			93.7						89.9						283.8						245.4
Gross Profit			90.4						95.8						267.4						284.4
Research and development expenses			8.4						8.2						24.7						25.3
Selling and general expenses			75.0						82.4						225.1						250.4
Other expense, net			3.4						5.3						33.7						10.0
Operating (Income) Loss			3.6						(0.1)						(16.1)						(1.3)
Interest income			0.2						0.2						0.2						1.1
Interest expense			(0.9)						(4.3)						(2.6)						(12.9)
Income (Loss) Before Income Taxes			2.9						(4.2)						(18.5)						(13.1)
Income tax (provision) benefit			(38.0)						23.5						13.7						33.1
Net (Loss) Income			$	(35.1)					$	19.3					$	(4.8)					$	20.0
Interest expense, net			$	0.7					$	4.1					$	2.4					$	11.8
Income tax provision (benefit)			38.0						(23.5)						(13.7)						(33.1)
Depreciation and amortization			9.6						10.7						28.8						32.1
EBITDA			$	13.2					$	10.6					$	12.7					$	30.8
(Loss) Earnings Per Share
Basic			$	(0.73)					$	0.40					$	(0.10)					$	0.42
Diluted			(0.73)						0.40						(0.10)						0.42
Common Shares Outstanding
Basic			48.1						47.8						48.1						47.8
Diluted			48.1						48.1						48.1						48.0

 

AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
			Gross Profit
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
As reported			$	90.4					$	95.8					$	267.4					$	284.4
COVID-19 related expenses			—						1.8						—						4.3
2020 Restructuring charges			1.1						—						4.1						—
Post divestiture restructuring charges			2.9						0.9						5.5						2.0
Post divestiture transition charges			—						0.6						3.8						1.7
Acquisition and integration-related charges			0.1						0.6						0.1						0.8
Intangibles amortization			1.7						1.7						5.0						5.0
As adjusted non-GAAP			$	96.2					$	101.4					$	285.9					$	298.2
Gross profit margin, as reported			49.1		%				51.6		%				48.5		%				53.7		%
Gross profit margin, as adjusted			52.3		%				54.6		%				51.9		%				56.3		%
			Operating (Loss) Profit
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
As reported			$	3.6					$	(0.1)					$	(16.1)					$	(1.3)
COVID-19 related expenses			—						3.2						0.2						6.9
2020 Restructuring charges(a)			1.7						—						10.4						—
Post divestiture restructuring charges			2.9						0.9						5.5						1.4
Post divestiture transition charges(b)			—						1.1						3.6						8.2
Acquisition and integration-related charges			0.1						5.7						0.7						9.6
EU MDR Compliance(c)			1.2						—						2.4						—
Litigation and legal(d)			3.3						2.4						28.5						5.8
Intangibles amortization			4.2						4.9						12.5						14.6
As adjusted non-GAAP			$	17.0					$	18.1					$	47.7					$	45.2

________________________
(a)	In the three months ended September 30, 2021, 2020 Restructuring charges includes $1.1 million in "Cost of products sold" (see "Gross Profit" table), $0.8 million in "Selling and general expenses" partially offset by $0.2 million of income in "Other expense, net." Likewise, in the nine months ended September 30, 2021, 2020 Restructuring includes $4.1 million in "Cost of products sold," $1.5 million in "Selling and general expenses" and $4.8 million in "Other expense, net."
(b)	In the three and nine months ended September 30, 2021, post divestiture transition charges include $— million and $3.8 million in "Cost of products sold" (see "Gross Profit" table) partially offset by a benefit of $— million and $0.2 million in "Selling and general expenses."
(c)	European Union Medical Device Regulation ("EU MDR") compliance related charges are included in "Selling and general expenses".
(d)	Litigation and legal expenses are included in "Other expense, net."

 

AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
			Income (Loss) Before Taxes
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
As reported			$	2.9					$	(4.2)					$	(18.5)					$	(13.1)
COVID-19 related expenses			—						3.2						0.2						6.9
2020 Restructuring charges			1.7						—						10.4						—
Post divestiture restructuring charges			2.9						0.9						5.5						1.4
Post divestiture transition charges			—						1.1						3.6						8.2
Acquisition and integration-related charges			0.1						5.7						0.7						9.6
EU MDR Compliance			1.2						—						2.4						—
Litigation and legal			3.3						2.4						28.5						5.8
Intangibles amortization			4.2						4.9						12.5						14.6
As adjusted non-GAAP			$	16.3					$	14.0					$	45.3					$	33.4
			Tax Benefit (Provision)
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
As reported			$	(38.0)					$	23.5					$	13.7					$	33.1
Tax effects of adjusting items			33.4						(3.8)						(23.6)						(11.2)
Effects of the CARES Act and other(a)			0.2						(23.5)						(2.3)						(31.0)
As adjusted non-GAAP			$	(4.4)					$	(3.8)					$	(12.2)					$	(9.1)
Effective tax rate, as reported			1310.3		%				559.5		%				74.1		%				252.7		%
Effective tax rate, as adjusted			27.0		%				27.1		%				26.9		%				27.2		%

______________________
(a)	The CARES Act, which allows for the carryback of U.S. net operating losses to prior years, provided an income tax benefit of $3.6 million in the nine months ended September 30, 2021 compared to $33.1 million last year.

 

AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions, except per share amounts)
			Net Income (Loss)
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
As reported			$	(35.1)					$	19.3					$	(4.8)					$	20.0
COVID-19 related expenses			—						3.2						0.2						6.9
2020 Restructuring charges			1.7						—						10.4						—
Post divestiture restructuring charges			2.9						0.9						5.5						1.4
Post divestiture transition charges			—						1.1						3.6						8.2
Acquisition and integration-related charges			0.1						5.7						0.7						9.6
EU MDR Compliance			1.2						—						2.4						—
Litigation and legal			3.3						2.4						28.5						5.8
Intangibles amortization			4.2						4.9						12.5						14.6
Tax effects of adjusting items			33.4						(3.8)						(23.6)						(11.2)
Tax effects of the CARES Act and other			0.2						(23.5)						(2.3)						(31.0)
As adjusted non-GAAP			$	11.9					$	10.2					$	33.1					$	24.3
Diluted EPS, as reported			$	(0.73)					$	0.40					$	(0.10)					$	0.42
Diluted EPS, as adjusted			$	0.25					$	0.21					$	0.69					$	0.51
			EBITDA
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
EBITDA, as reported			$	13.2					$	10.6					$	12.7					$	30.8
COVID-19 related expenses			—						3.2						0.2						6.9
2020 Restructuring charges			1.7						—						10.4						—
Post divestiture restructuring charges			2.9						0.9						5.5						1.4
Post divestiture transition charges			—						1.1						3.6						8.2
Acquisition and integration-related charges			0.1						5.7						0.7						9.6
EU MDR Compliance			1.2						—						2.4						—
Litigation and legal			3.3						2.4						28.5						5.8
Adjusted EBITDA			$	22.4					$	23.9					$	64.0					$	62.7

 

AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
			Free Cash Flow
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
Cash provided by (used in) operating activities			$	23.2					$	1.1					$	35.2					$	(3.6)
Capital expenditures			(4.8)						(3.0)						(16.3)						(15.1)
Free Cash Flow			$	18.4					$	(1.9)					$	18.9					$	(18.7)

 

2021 OUTLOOK
			Estimated Range
Diluted earnings per share (GAAP)			$	0.02		to			$	0.26
Intangibles amortization			0.26			to			0.26
Restructuring initiatives			0.20			to			0.16
Litigation and legal			0.52			to			0.46
Other			0.10			to			0.06
Adjusted diluted earnings per share (non-GAAP)			$	1.10		to			$	1.20

 

AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
			September 30, 2021						December 31, 2020
ASSETS
Current Assets
Cash and cash equivalents			$	97.8					$	111.5
Accounts receivable, net of allowances			129.1						167.9
Inventories			158.4						168.9
Prepaid expenses and other current assets			19.7						18.9
Total Current Assets			405.0						467.2
Property, Plant and Equipment, net			169.7						175.3
Operating Lease Right-of-Use Assets			41.4						48.3
Goodwill			801.8						802.5
Other Intangible Assets, net			145.3						157.7
Deferred Tax Assets			23.6						10.0
Other Assets			11.1						11.8
TOTAL ASSETS			$	1,597.9					$	1,672.8
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Current portion of operating lease obligations			$	14.7					$	15.5
Trade accounts payable			54.9						67.6
Accrued expenses			59.6						83.2
Total Current Liabilities			129.2						166.3
Long-Term Debt			145.0						180.0
Operating Lease Liabilities			46.1						53.3
Deferred Tax Liabilities			5.6						5.7
Other Long-Term Liabilities			10.1						11.0
TOTAL LIABILITIES			336.0						416.3
Stockholders' Equity			1,261.9						1,256.5
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY			$	1,597.9					$	1,672.8

 

AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
(unaudited)
(in millions)
			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
Operating Activities
Net (loss) income			$	(35.1)					$	19.3					$	(4.8)					$	20.0
Depreciation and amortization			9.6						10.7						28.8						32.1
Net loss on asset dispositions and impairments			—						1.1						4.9						1.3
Changes in operating assets and liabilities			7.9						(9.6)						11.4						(34.6)
Deferred income taxes and other			40.8						(20.4)						(5.1)						(22.4)
Cash Provided by (Used in) Operating Activities			23.2						1.1						35.2						(3.6)
Investing Activities
Capital expenditures			(4.8)						(3.0)						(16.3)						(15.1)
Acquisition of assets and investments in businesses			—						(4.0)						—						(4.0)
Cash Used in Investing Activities			(4.8)						(7.0)						(16.3)						(19.1)
Financing Activities
Revolving credit facility proceeds			20.0						—						20.0						—
Revolving credit facility repayments			(40.0)						—						(55.0)						—
Purchase of treasury stock			(0.1)						(0.1)						(0.6)						(0.4)
Proceeds from the exercise of stock options			0.9						0.8						6.1						1.4
Payment of contingent consideration liabilities			—						(2.7)						—						(2.7)
Cash Used in Financing Activities			(19.2)						(2.0)						(29.5)						(1.7)
Effect of Exchange Rate Changes on Cash and Cash Equivalents			(1.3)						2.9						(3.1)						(0.9)
Decrease in Cash and Cash Equivalents			(2.1)						(5.0)						(13.7)						(25.3)
Cash and Cash Equivalents - Beginning of Period			99.9						185.0						111.5						205.3
Cash and Cash Equivalents - End of Period			$	97.8					$	180.0					$	97.8					$	180.0

 

AVANOS MEDICAL, INC.
SELECTED BUSINESS AND PRODUCTS DATA
(unaudited)
(in millions)
			Three Months Ended September 30,																		Nine Months Ended September 30,
			2021						2020						Change						2021						2020						Change
Chronic care			$	117.1					$	119.3					(1.8)		%				$	354.2					$	355.2					(0.3)		%
Pain management			67.0						66.4						0.9						197.0						174.6						12.8
Total Net sales			$	184.1					$	185.7					(0.9)		%				$	551.2					$	529.8					4.0		%
									Total						Volume						Pricing/Mix						Currency						Other(a)
Net Sales - percentage change			QTD						(1)		%				—		%				(1)		%				—		%				—		%
			YTD						4		%				4		%				(1)		%				1		%				—		%

_____________
(a)	Other includes rounding.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-announces-third-quarter-2021-results-301413550.html

SOURCE Avanos Medical, Inc.

FAQ

What were Avanos Medical's Q3 2021 net sales figures?

Avanos Medical reported Q3 2021 net sales of $184 million.

Did Avanos Medical experience a profit or loss in Q3 2021?

Avanos Medical posted a net loss of $35 million in Q3 2021.

How did Avanos Medical's gross margin change in Q3 2021?

The gross margin for Q3 2021 was 49%, down from 52% in the prior year.

What was the adjusted net income for Avanos Medical in Q3 2021?

The adjusted net income for Q3 2021 was $12 million, compared to $10 million the previous year.

What were the primary factors affecting Avanos Medical's financial performance in Q3 2021?

The financial performance was impacted by delays in elective procedures and rising freight costs.